These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 26813930)

  • 1. Fasiglifam/TAK-875, a Selective GPR40 Agonist, Improves Hyperglycemia in Rats Unresponsive to Sulfonylureas and Acts Additively with Sulfonylureas.
    Ito R; Tsujihata Y; Suzuki M; Miyawaki K; Matsuda K; Takeuchi K
    J Pharmacol Exp Ther; 2016 Apr; 357(1):217-27. PubMed ID: 26813930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TAK-875, an orally available G protein-coupled receptor 40/free fatty acid receptor 1 agonist, enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia in type 2 diabetic rats.
    Tsujihata Y; Ito R; Suzuki M; Harada A; Negoro N; Yasuma T; Momose Y; Takeuchi K
    J Pharmacol Exp Ther; 2011 Oct; 339(1):228-37. PubMed ID: 21752941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CPL207280, a Novel G Protein-Coupled Receptor 40/Free Fatty Acid Receptor 1-Specific Agonist, Shows a Favorable Safety Profile and Exerts Antidiabetic Effects in Type 2 Diabetic Animals.
    Bazydlo-Guzenda K; Buda P; Matloka M; Mach M; Stelmach F; Dzida R; Smuga D; Hucz-Kalitowska J; Teska-Kaminska M; Vialichka V; Dubiel K; Kaminska B; Wieczorek M; Pieczykolan J
    Mol Pharmacol; 2021 Oct; 100(4):335-347. PubMed ID: 34349026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TAK-875, a GPR40/FFAR1 agonist, in combination with metformin prevents progression of diabetes and β-cell dysfunction in Zucker diabetic fatty rats.
    Ito R; Tsujihata Y; Matsuda-Nagasumi K; Mori I; Negoro N; Takeuchi K
    Br J Pharmacol; 2013 Oct; 170(3):568-80. PubMed ID: 23848179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel antidiabetic drug, fasiglifam/TAK-875, acts as an ago-allosteric modulator of FFAR1.
    Yabuki C; Komatsu H; Tsujihata Y; Maeda R; Ito R; Matsuda-Nagasumi K; Sakuma K; Miyawaki K; Kikuchi N; Takeuchi K; Habata Y; Mori M
    PLoS One; 2013; 8(10):e76280. PubMed ID: 24130766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Free fatty acid receptor 1 agonist, MR1704, lowers blood glucose levels in rats unresponsive to the sulfonylurea, glibenclamide.
    Tsuda N; Kawaji A; Takagi M; Higashi C; Nakamura M; Hosaka Y; Sakaki J
    Drug Dev Res; 2018 Feb; 79(1):16-21. PubMed ID: 29080222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of Potent and Orally Bioavailable GPR40 Full Agonists Bearing Thiophen-2-ylpropanoic Acid Scaffold.
    Li H; Huang Q; Chen C; Xu B; Wang HY; Long YQ
    J Med Chem; 2017 Apr; 60(7):2697-2717. PubMed ID: 28277660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GPR40-induced insulin secretion by the novel agonist TAK-875: first clinical findings in patients with type 2 diabetes.
    Araki T; Hirayama M; Hiroi S; Kaku K
    Diabetes Obes Metab; 2012 Mar; 14(3):271-8. PubMed ID: 22051148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Xelaglifam, a novel GPR40/FFAR1 agonist, exhibits enhanced β-arrestin recruitment and sustained glycemic control for type 2 diabetes.
    Yoon J; Lee DG; Song H; Hong D; Park JS; Hong C; An KM; Lee JW; Park JT; Yoon H; Tak J; Kim SG
    Biomed Pharmacother; 2024 Aug; 177():117044. PubMed ID: 38941892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GPR40-Mediated G
    Rives ML; Rady B; Swanson N; Zhao S; Qi J; Arnoult E; Bakaj I; Mancini A; Breton B; Lee SP; Player MR; Pocai A
    Mol Pharmacol; 2018 Jun; 93(6):581-591. PubMed ID: 29572336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of a novel potent GPR40 full agonist.
    Meegalla SK; Huang H; Martin T; Xu J; Zhao S; Liu J; Hall M; Gunnet J; Wang Y; Rady B; Silva J; Otieno M; Arnoult E; Paul Lee S; Pocai A; Player MR
    Bioorg Med Chem Lett; 2018 Feb; 28(4):720-726. PubMed ID: 29366647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term safety and efficacy of fasiglifam (TAK-875), a G-protein-coupled receptor 40 agonist, as monotherapy and combination therapy in Japanese patients with type 2 diabetes: a 52-week open-label phase III study.
    Kaku K; Enya K; Nakaya R; Ohira T; Matsuno R
    Diabetes Obes Metab; 2016 Sep; 18(9):925-9. PubMed ID: 27178047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute administration of GPR40 receptor agonist potentiates glucose-stimulated insulin secretion in vivo in the rat.
    Doshi LS; Brahma MK; Sayyed SG; Dixit AV; Chandak PG; Pamidiboina V; Motiwala HF; Sharma SD; Nemmani KV
    Metabolism; 2009 Mar; 58(3):333-43. PubMed ID: 19217448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fasiglifam as a new potential treatment option for patients with type 2 diabetes.
    Kaku K
    Expert Opin Pharmacother; 2013 Dec; 14(18):2591-600. PubMed ID: 24195772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of fasiglifam (TAK-875), a G protein-coupled receptor 40 agonist, in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial.
    Kaku K; Enya K; Nakaya R; Ohira T; Matsuno R
    Diabetes Obes Metab; 2015 Jul; 17(7):675-81. PubMed ID: 25787200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CNX-011-67, a novel GPR40 agonist, enhances glucose responsiveness, insulin secretion and islet insulin content in n-STZ rats and in islets from type 2 diabetic patients.
    Sunil V; Verma MK; Oommen AM; Sadasivuni M; Singh J; Vijayraghav DN; Chandravanshi B; Shetty J; Biswas S; Dandu A; Moolemath Y; Venkataranganna MV; Somesh BP; Jagannath MR
    BMC Pharmacol Toxicol; 2014 Mar; 15():19. PubMed ID: 24666736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis, and biological activity of potent and orally available G protein-coupled receptor 40 agonists.
    Sasaki S; Kitamura S; Negoro N; Suzuki M; Tsujihata Y; Suzuki N; Santou T; Kanzaki N; Harada M; Tanaka Y; Kobayashi M; Tada N; Funami M; Tanaka T; Yamamoto Y; Fukatsu K; Yasuma T; Momose Y
    J Med Chem; 2011 Mar; 54(5):1365-78. PubMed ID: 21319751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of the molecular mode of action of the sulfonylurea, glimepiride, at adipocytes.
    Müller G; Geisen K
    Horm Metab Res; 1996 Sep; 28(9):469-87. PubMed ID: 8911985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of GPR40 as a therapeutic target for the treatment of type 2 diabetes.
    Burant CF
    Diabetes Care; 2013 Aug; 36 Suppl 2(Suppl 2):S175-9. PubMed ID: 23882043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular effects of conventional sulfonylureas and glimepiride.
    Geisen K; Végh A; Krause E; Papp JG
    Horm Metab Res; 1996 Sep; 28(9):496-507. PubMed ID: 8911987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.